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Abstract
 
Lymphocytes deficient in the T cell costimulatory molecule CD28 exhibit defects in cell sur-
vival, clonal expansion, and differentiation into effector cells. It is known that CD28-mediated
 
signaling results in the upregulation of the Bcl family member Bcl-X
 
L
 
. To investigate the role
that Bcl-X
 
L
 
 plays in the various functions of CD28, we expressed Bcl-X
 
L
 
 in CD28-deficient
primary T lymphocytes using retrovirus-mediated gene transfer. T cells were activated in vitro
and infected with Bcl-X
 
L
 
 or control retroviruses; this method allows gene expression in acti-
vated, cycling cells. Expression of Bcl-X
 
L
 
 in naive T cells was achieved by reconstitution of the
immune system of lethally irradiated recipient mice with retrovirus-infected purified bone
 
marrow stem cells from CD28
 
2
 
/
 
2
 
 or wild-type donor mice. Our studies demonstrate that Bcl-
X
 
L
 
 prolongs the survival of CD28
 
2
 
/
 
2
 
 T cells but does not restore normal proliferation or effec-
tor cell development. These results indicate that the various functions of CD28 can be dissoci-
ated, and provide an experimental approach for testing the roles of downstream signals in the
functions of cellular receptors such as CD28.
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Introduction
 
The functional responses of T lymphocytes are initiated by
the recognition of antigens and costimulators expressed on
professional APCs (1, 2). The best-described costimulatory
pathway involves the B7 molecules on APCs and their re-
ceptor, CD28, on T cells (3, 4). Ligation of CD28 by B7
promotes the survival of T cells by stimulating expression
 
of the antiapoptotic protein Bcl-X
 
L
 
 (5–7) and enhances
IL-2 production and sustained IL-2–driven T cell prolifera-
tion (8). In addition, CD28 is required for the development
of Th2 effectors from naive CD4 T cells. Mice lacking
CD28 show reduced T cell clonal expansion in response to
antigen, and a marked defect in Th2-dependent responses
(9–11).
We have initiated a gene complementation approach for
identifying the key intracellular signals triggered by CD28,
and for determining how these signals relate to functional
responses. The principle of this approach is to express, by
retrovirus-mediated gene transfer, genes encoding various
signaling or antiapoptotic proteins in normal T cells lacking
CD28. By assaying the functional responses of these recon-
stituted T cells to various stimuli, we can determine if the
 
expressed genes restore any or all of the defects of CD28
 
2
 
/
 
2
 
T cells. The first gene we have chosen to establish this
approach is Bcl-X
 
L
 
, for several reasons. First, Bcl-X
 
L
 
 is rap-
idly induced in T cells upon antigen recognition and co-
stimulation via CD28. Second, defective survival is a major
abnormality in CD28
 
2
 
/
 
2
 
 T cells, and it is possible that this
alone accounts for the multiple functional defects associated
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Bcl-X
 
L
 
 in CD28-deficient T Cells
 
with the absence of CD28. The following studies demon-
strate that expression of Bcl-X
 
L
 
 in CD28
 
2
 
/
 
2
 
 T cells both in
vitro and in vivo prolongs the survival of these cells but
does not correct the observed defects in proliferation and
Th2 differentiation. Thus, CD28 is involved in multiple
biological responses of T cells, and these responses are
likely to be mediated by different intracellular biochemical
pathways.
 
Materials and Methods
 
Mice.
 
DO.11 transgenic mice expressing a TCR recognizing
the hen egg white ovalbumin peptide, OVA 323–339, in the
context of the MHC class II molecule I-A
 
d
 
 (12) were obtained
from Dr. Dennis Loh (Hoffman-La Roche, Inc., Nutley, NJ).
Crosses of DO.11 mice with CD28-deficient mice were obtained
from Dr. Jeff Bluestone (University of Chicago, Chicago, IL).
BALB/c mice, 6–8 wk old, were purchased from The Jackson
Laboratory. All mice were bred and maintained in accordance
with the guidelines of the Committee on Animals of the Harvard
Medical School, and those prepared by the Committee of Care
and Use of Laboratory Animal Resources, National Research
Council.
 
Generation of Recombinant Retrovirus.
 
The murine stem cell
virus (MSCV) 2.2 vector (13) modified to contain an internal ri-
bosomal binding site, IRES (Novagen), and the cDNA of green
fluorescent protein (GFP)
 
1
 
 (hGFP S65T; CLONTECH Labora-
tories, Inc.) were gifts of Dr. Bill Sha (University of California at
Berkeley, Berkeley, CA; 14). In this vector, a foreign cDNA is
inserted in front of the IRES element and the GFP cDNA so that
one long transcript encompassing the foreign cDNA and the GPF
cDNA is generated under control of the LTR from the pCMV
mutant myeloproliferative sarcoma virus. The human Bcl-X
 
L
 
cDNA (15) was a gift of Dr. Gabriel Nunez (University of Mich-
igan, Ann Arbor, MI). Human Bcl-X
 
L
 
 has been demonstrated to
be functional in mouse cells (16). The Bcl-X
 
L
 
 cDNA was cloned
into MSCV2.2 IRES GFP as a XhoI-XhoI fragment to generate
MSCV2.2 Bcl-X
 
L
 
 IRES GFP (MS-Bcl-X
 
L
 
).
Virus used for infection of primary T cells was produced by
transfecting the ecotropic packaging cell line Phoenix E (ob-
tained from Dr. G. Nolan, Stanford University, Stanford, CA)
with MS or MS-Bcl-X
 
L
 
 plasmid described above. Supernatants
were collected at days 2 and 3 after transfection and either used
directly for infection of target cells or snap frozen in liquid nitro-
gen and stored at 
 
2
 
80
 
8
 
C. The titer of different virus stocks was
determined by infecting a fixed number of NIH3T3 cells and
measuring GFP expression in infected cells at 48 h after infection.
Virus used for infection of bone marrow stem cells was produced
by transfecting the vesicular stomatitis virus G protein producing
packaging cell line, 293 GPG (17), with control or Bcl-X
 
L
 
 plas-
mid. The pseudotyped virus in the cell supernatant was harvested
over 7 consecutive days and concentrated by ultracentrifugation
to titers of 10
 
8
 
–10
 
9
 
 infectious particles per milliliter.
 
T Cell Culture and Infection with Recombinant Retrovirus In
Vitro.
 
Spleen and lymph node cells were collected from DO.11
wild-type (WT) and CD28
 
2
 
/
 
2
 
 mice. The cells were depleted of
red blood cells, purified by centrifugation on a Ficoll Paque gra-
dient (Amersham Pharmacia Biotech), and activated at 3 
 
3
 
 10
 
6
 
cells/ml with 1 
 
m
 
g/ml OVA 323–339 peptide in 24-well plates
in a total volume of 1 ml. The culture medium consisted of
RPMI 1640 supplemented with 2 mM glutamine, penicillin,
streptomycin, nonessential amino acids, sodium pyruvate, 10 mM
Hepes (all from GIBCO BRL), 5 
 
3
 
 10
 
2
 
5 
 
M 2-ME (Bio-Rad),
and 10% heat-inactivated FCS (Sigma-Aldrich). After 24 h, the
cells were collected, counted, and replated in a 24-well plate at
1.25 
 
3 
 
10
 
6
 
 cells/ml in 2 ml retroviral supernatant containing 8
 
m
 
g/ml lipofectamine (GIBCO BRL). The culture plates were
then centrifuged at 1,800 rpm for 45 min at room temperature.
The following day, 1.5 ml of the viral inoculum was replaced
with fresh culture medium. The cells were split 1:2 or 1:3 on that
day or the day after, depending on cell density, and were col-
lected, Ficolled, and analyzed by flow cytometry at day 3 after in-
fection. The cells were then either used directly in restimulation
cultures or, if indicated, stained with TCR (KJ1-26) (18) and
CD4-specific antibodies and sorted on a MoFlo high-speed cell
sorter (see below). For restimulation, 2.5 
 
3
 
 10
 
5
 
 cells were cul-
tured with 2.5 
 
3
 
 10
 
6
 
 mitomycin C–treated BALB/c splenocytes
(APCs) and 0.1 or 1 
 
m
 
g/ml OVA peptide in a volume of 1 ml/
well in a 24-well plate.
 
Transplantation of Retrovirus-infected Purified Bone Marrow Stem
Cells.
 
Sca-1
 
1
 
Lin
 
2
 
 bone marrow stem cells were isolated from
femoral bone marrow of WT DO.11 or CD28
 
2
 
/
 
2
 
 DO.11 mice
and cultured in 50 ng/ml murine stem cell factor (mSCF), 50 ng/
ml human flt3 ligand, 200 U/ml murine IL-6, and 200 U/ml
murine IL-3, all from R&D Systems. After 2–3 d, the cells were
infected with pseudotyped virus as follows. Concentrated virus
was added to precooled cells in the presence of polybrene (8 
 
m
 
g/
ml; Sigma-Aldrich), and after an initial incubation at 4
 
8
 
C, the
cells were transferred to a 37
 
8
 
C incubator and left for an addi-
tional period of 2–3 h. Then, the cells were washed and injected
into lethally (1,200 rads) irradiated 10–12-wk-old male BALB/c
mice by tail vein injection.
 
Assays of Proliferation and Cytokine Production.
 
Proliferation of
T cells was assayed by incubating 2.5 
 
3
 
 10
 
4
 
 T cells with 2.5 
 
3
 
10
 
5 
 
mitomycin C–treated BALB/c splenocytes and a range of dif-
ferent peptide concentration for 1–3 d. During the final 8–10 h
of culture, the cells were pulsed with 1 
 
m
 
Ci of 
 
3
 
[H]thymidine and
then harvested for liquid scintillation counting. The concentra-
tions of cytokines in culture supernatants were measured on days
1–3 by ELISA using anticytokine antibodies from BD PharMin-
gen. Cytokine production by individual cells was assessed by in-
tracellular cytokine staining (see below).
 
Flow Cytometry.
 
T cell cultures were analyzed for the pres-
ence of the TCR and CD4 by incubation with biotinylated KJ1-
26 followed by incubation with PE-conjugated streptavidin (BD
PharMingen) and CyC-conjugated anti–murine CD4 antibody
(BD PharMingen). All surface stains were done in PBS, 1% BSA,
0.01% sodium azide and the cells were analyzed immediately after
staining without fixation. When cell sorting was required, a Mo-
Flo high-speed cell sorter (Cytomation) was used.
For intracellular cytokine stains, 5 
 
3
 
 10
 
5
 
 cells in a volume of
200 
 
m
 
l medium were activated in the presence of 10 ng/ml PMA
(Sigma-Aldrich) and 1 
 
m
 
M calcium ionophore (A23187; Sigma-
Aldrich) in 96-well plates for 4–6 h. During the last 2 h of activa-
tion, brefeldin A was included to give a final concentration of 10
 
m
 
g/ml. The cells were washed once in PBS, fixed for 10 min
with 200 
 
m
 
l 2% (wt/vol) formaldehyde (Polysciences) in PBS,
and washed twice with PBS and once with 0.5% (wt/vol) sapo-
nin (Sigma-Aldrich), 1% (wt/vol) BSA (Sigma-Aldrich), and
0.01% (wt/vol) sodium azide (PBS/saponin). The cells were
stained with PE-conjugated antibodies against murine IL-2, IL-4,
 
1
 
Abbreviations used in this paper:
 
 GFP, green fluorescent protein; WT,
wild-type. 
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IFN-
 
g
 
, or a PE-conjugated rat IgG1 isotype control. All antibod-
ies were diluted to 10 
 
m
 
g/ml in PBS/saponin. The cells were
subsequently washed twice with PBS/saponin and once with
PBS, and then stained for surface CD4 as described above. Im-
mediately after the surface stain, the cells were washed twice with
PBS, resuspended in PBS/1% BSA, and analyzed by FACS
 
®
 
.
 
Western Blots.
 
T cells infected with control virus or Bcl-X
 
L
 
virus were lysed in RIPA buffer (150 mM NaCl, 1% NP-40,
0.5% deoxycholic acid, 0.5% SDS, and 50 mM Tris-HCl, pH
8.0) to give a concentration of 10
 
8
 
 cells/ml. Proteins in cell ly-
sates from 2 
 
3 
 
10
 
6
 
 cells were separated by SDS-PAGE in a 15%
gel, blotted onto a polyvinylidene difluoride (PVDF) membrane,
and probed with 1 
 
m
 
g/ml of a rabbit polyclonal Bcl-X
 
L/S
 
 antise-
rum (Santa Cruz Biotechnology) followed by incubation with a
horseradish peroxidase–conjugated anti–rabbit antibody (ICN
Biomedicals), and developed using an enhanced chemilumines-
cence kit (Amersham Pharmacia Biotech).
 
Results
 
Retrovirus-mediated Expression of Bcl-X
 
L
 
 in T Cells Activated
In Vitro.
 
To establish the system for introducing genes
into CD28
 
2
 
/
 
2
 
 T cells, we activated DO.11 WT and
DO.11 CD28
 
2
 
/
 
2
 
 T cells for 24 h with OVA peptide and
then incubated the cells with virus expressing GFP only
(control virus) or virus expressing human Bcl-X
 
L
 
 (Bcl-X
 
L
 
virus). Analysis of GFP expression at 72 h after infection
showed that 
 
.
 
30% of the DO.11 T cells were GFP
 
1
 
 (Fig.
1 A). This was true even for the CD28
 
2
 
/
 
2
 
 T cells, despite
lower levels of proliferation and expansion compared with
WT cells. Western blot analysis of the infected cells dem-
onstrated that Bcl-X
 
L
 
 protein was present in WT cells in-
fected with the control virus, was virtually undetectable in
the CD28
 
2
 
/
 
2
 
 cells, and was readily detectable in CD28
 
2
 
/
 
2
 
cells infected with the Bcl-X
 
L
 
 virus (Fig. 1 B). Thus, the
retrovirus infection method leads to the expression of the
introduced cDNA.
 
Bcl-X
 
L
 
 Expression Does Not Enhance Proliferation or Th2
Differentiation of In Vitro–infected CD28
 
2
 
/
 
2 T Cells. After
confirming that the retrovirus-introduced Bcl-XL protein
was expressed in T cells lacking CD28, we asked whether
Bcl-XL expression in CD282/2 T cells could correct the
previously described defects in survival, proliferation, and
Th2 differentiation. CD282/2 T cells were activated in
vitro with OVA peptide and APCs, and the cells were in-
fected with either control virus or Bcl-XL virus. The viable
cells were then collected, cultured with medium alone (no
stimulus) or IL-2, and assayed at various time points for to-
tal cell numbers as well as the percentage of CD41KJ1-261
cells that were GFP1 (Fig. 2). In the absence of IL-2, the
number of recovered viable cells remained constant for up
to 8 d. However, the proportion of GFP1 cells in the Bcl-
XL virus–infected population increased progressively (Fig.
2). This result suggests that Bcl expression promotes cell
survival but not expansion. Consistent with this result,
when the cells were cultured in IL-2, the total numbers of
recovered cells increased in both the control virus– and
Bcl-XL virus–infected populations but the proportion of
GFP1 cells remained constant (Fig. 2). Therefore, expres-
sion of Bcl-XL does not provide a selective growth advan-
tage to T cells induced to proliferate with IL-2.
To assess the role of Bcl-XL in T cell proliferation in-
duced by antigen and APCs, the virally infected cells (WT
with control virus, CD282/2 with control virus, and
CD282/2 with Bcl-XL virus) were sorted into GFPhigh
KJ1-261CD41 populations. The sorted cells were cultured
for an additional 3 d with APCs and OVA peptide (to ex-
pand cell numbers for staining) and re-analyzed for GFP
expression on day 3. At this time, .90% of the CD4 T
cells infected with Bcl-XL virus and sorted on the basis of
high GFP expression remained GFPhigh (Fig. 3 A). The
sorted populations were stimulated with antigen and APCs,
and proliferation was assayed. These experiments showed
that the CD282/2 T cells proliferated much less than the
WT T cells, and that Bcl-XL expression did not restore
normal proliferation (Fig. 3 B). In some experiments, a
Figure 1. Retrovirus-mediated expression of Bcl-XL in DO.11 WT
and DO.11 CD282/2 primary T lymphocytes. T cells were activated in
vitro with OVA peptide and APCs and infected on day 1 with retrovirus
encoding either GFP alone (control virus) or Bcl-XL and GFP (Bcl-XL vi-
rus). (A) Cells were collected and stained at day 3 after viral infection with
antibodies to CD4 and the DO.11 TCR (KJ1-26) and analyzed for GFP
expression in CD41KJ1-261 cells by flow cytometry. The number beside
the FACS® plot represents the percentage of CD41KJ1-261 T cells. FSC,
forward scatter. (B) Cells infected with retrovirus containing GFP alone
or GFP/Bcl-XL as in A were cultured for an additional 4 d in the presence
of APCs and OVA peptide, collected, lysed, and analyzed by Western
blotting with a polyclonal antiserum specific for Bcl-XL/S protein.2034 Bcl-XL in CD28-deficient T Cells
small increase in the proliferative response was observed on
day 3 in the CD282/2 lymphocytes expressing Bcl-XL.
This was most likely due to the fact that Bcl-XL expression
promoted the survival of greater numbers of CD282/2 T
cells, thus leading to a gradual increase in total cell numbers
in each culture well and therefore an increase in total DNA
synthesis per well.
To evaluate the effect of Bcl-XL on T cell differentia-
tion, the WT or CD282/2 DO.11 lymphocytes infected
with control or Bcl-XL virus were sorted into GFPhighKJ1-
261CD41 populations as described above. The GFPhigh
populations were then restimulated with OVA peptide and
APCs, and culture supernatants were analyzed for IL-2, IL-
4, and IL-5 by ELISA. As demonstrated in Fig. 4, CD282/2
T cells produced much less of these cytokines than did
WT T cells, and Bcl-XL expression did not restore cyto-
kine production. Therefore, although expression of Bcl-XL
clearly enhances the survival of CD282/2 lymphocytes, it
does not correct the defects in effector cell development
that are seen in these costimulator-deficient cells.
Expression of Bcl-XL in Naive CD282/2 T Cells by Recon-
stitution of Lethally Irradiated Mice with Retrovirus-infected
Bone Marrow Stem Cells. One of the limitations of the in
vitro infection method is that only cells that are cycling can
be infected, thus restricting this technique to activated T
cells. To express genes in naive T cells, we infected Sca-
11Lin2 purified bone marrow stem cells from WT or
CD282/2 DO.11 TCR transgenic mice, and used the
Figure 2. Expression of Bcl-XL promotes the survival of
CD282/2 T cells. T cells were activated with OVA pep-
tide and APCs and infected with control virus or Bcl-XL
virus as in the legend to Fig. 1. 3 d after infection, the cells
were collected, Ficolled (to remove dead cells, antigen,
and APCs), and put into culture with medium alone (no
stimulus) or IL-2 at 50 U/ml. Cells were then harvested
from the wells and counted 2, 4, 6, and 8 d after reculture
(left). Aliquots of the cells were stained with anti-CD4 and
anti–KJ1-26 and analyzed by flow cytometry. The per-
centage of CD41KJ1-261 GFP1 cells was then deter-
mined (right).
Figure 3. Expression of Bcl-XL in CD282/2 T cells does not restore normal proliferation. DO.11 WT
or DO.11 CD282/2 T cells activated in vitro were infected with control or Bcl-XL virus on day 1 (as de-
scribed in the legend to Fig. 1) and harvested 3 d later. Using a Cytomation MoFlo high speed sorter, the
CD41KJ1-261 cells expressing high levels of GFP were collected. The cells were then plated in 24-well
plates at 2.5 3 105 T cells/well with 2.5 3 106 APCs and 1 mg/ml peptide or in 96-well plates at 2.5 3
104 T cells/well with 2.5 3 105 APCs and a range of OVA peptide concentrations. (A) After 4 d of cul-
ture in 24-well plates with APCs and OVA peptide, the cells were collected and stained with antibodies
to CD4. The cells were then analyzed by flow cytometry for GFP expression in the CD41 population.
(B) The microcultures of DO.11 WT or DO.11 CD282/2 GFPhigh T cells fractions stimulated with APCs and OVA peptide were pulsed with [3H]thymi-
dine for 6 h on days 1 and 3, and the incorporated radioactivity was measured.2035 Dahl et al.
transduced bone marrow to reconstitute lethally irradiated
BALB/c recipients. CD41KJ1-261 cells were observed in
the peripheral blood from 5–6 wk after transfer (Fig. 5 A).
The numbers of CD41KJ1-261 cells in the spleen and
lymph nodes were similar in mice reconstituted with
DO.11 WT bone marrow stem cells or with CD282/2
DO.11 bone marrow stem cells (Fig. 5 A), and 15–50% of
the mature DO.11 T cells that developed also expressed
GFP (Fig. 5 B). Thus, expression of Bcl-XL does not alter
the maturation of the T cells. However, Bcl-XL expression
did give the cells a survival advantage, because in mice re-
constituted with the Bcl-XL virus, the percentage of GFP1
cells among mature lymphocytes was significantly greater
than in mice reconstituted with control virus–infected pre-
cursors.
To evaluate the function of Bcl-XL in the bone marrow–
reconstituted CD282/2 T cells, CD41 T cells were col-
lected from the spleen and lymph nodes of reconstituted
mice and cultured with APCs and OVA peptide. Prolifera-
tive responses of the naive T cells were measured on days 1
and 2 of culture. As was found in the previously described
in vitro retroviral infection experiments, expression of Bcl-
XL in the naive CD282/2 lymphocytes via bone marrow
reconstitution did not restore their proliferative capacity
(Fig. 6).
The previous experiments investigating the role of Bcl-
XL in the effector differentiation of CD282/2 T cells relied
on infecting the cells after T cell activation by antigen had
taken place. We were therefore interested to determine if
expression of Bcl-XL in naive CD282/2 T cells could pro-
mote the production of IL-4 by these cells. Lymph node T
cells from bone marrow–reconstituted mice were cultured
with antigen and APCs, and IL-4 production was measured
by intracellular staining, gating on GFP1 cells. As was
observed with the introduction of Bcl-XL into in vitro–
activated CD282/2 T cells, the presence of Bcl-XL at the
initiation of activation did not restore differentiation into
IL-4–producing effector cells (Fig. 7).
Discussion
The studies described in this paper were designed to es-
tablish a method for gene complementation in lymphocytes
lacking selected proteins and to use this method to begin to
define the specific functions of various molecules associated
Figure 4. Expression of Bcl-XL does not restore normal cytokine pro-
duction in CD282/2 T cells. Activated DO.11 WT (black bars) or DO.11
CD282/2 GFPhigh T cells (expressing control virus [white bars] or Bcl-XL
virus [hatched bars]) were generated as described in the legend to Fig. 3.
These cells were then cultured with OVA peptide (1 mg/ml) and mitomy-
cin C–treated APCs in 24-well plates. After 12 h of restimulation, super-
natants were harvested and analyzed for IL-2, IL-4, and IL-5 by ELISA.
Figure 5. Reconstitution of lethally irradiated mice with purified bone
marrow stem cells infected with recombinant Bcl-XL retrovirus. Lethally
irradiated BALB/c mice were reconstituted with stem cells purified from
bone marrow of DO.11 WT or DO.11 CD282/2 mice infected with
control retrovirus or with retrovirus expressing Bcl-XL. (A) Spleen and
lymph nodes were harvested at 6–7 wk after transfer and analyzed for
KJ1-26 and CD4 expression by flow cytometry. The BALB/c control
was a nonirradiated age- and sex-matched mouse. Irradiated BALB/c
mice that did not receive any bone marrow died within 10 d of treat-
ment. (B) FACS® analysis of GFP expression in CD41KJ1-261 cells from
peripheral blood, spleen, and lymph nodes of BALB/c mice reconstituted
with purified DO.11 CD282/2 bone marrow stem cells infected with
Bcl-XL virus.2036 Bcl-XL in CD28-deficient T Cells
with CD28-mediated signals. It was essential to express
genes in primary lymphocytes so that we could assay a vari-
ety of responses as well as target lymphocytes from various
knockout mouse strains. In these initial experiments, we
have asked if the antiapoptotic protein Bcl-XL can correct
the functional defects of T cells lacking CD28.
We chose to focus on Bcl-XL, as this antiapoptotic pro-
tein is directly induced by CD28 costimulation. Further-
more, the failure of sustained responses of CD282/2 T cells
has been postulated to result primarily from an absence of
Bcl-XL and decreased cell survival. Using a retroviral con-
struct that gives efficient expression from a bicistronic mes-
sage, we have achieved high expression of the marker gene
(GFP) as well as the gene of interest (Bcl-XL) in primary
naive and activated T cells. Western blot analysis of bulk
cultures infected with Bcl-XL GFP virus showed that these
cell populations express the Bcl-XL protein. We also found
that cells infected with the Bcl-XL virus had the expected
survival advantage over cells infected with control virus,
thereby demonstrating that the introduced Bcl-XL gene
was functional. The ability to use the GFP-containing vec-
tor for gene expression both in in vitro–activated lympho-
cytes and in bone marrow–derived cells greatly increases
the potential utility of this retroviral method. Infection of
in vitro–activated lymphocytes allows for rapid screening of
candidate genes for effector function at early and late stages
of lymphocyte activation, whereas stable gene expression in
bone marrow–derived cells allows us to examine the con-
sequences of expressing selected genes in developing lym-
phocytes and in naive (unstimulated) lymphocytes.
The analyses of CD282/2 T cells that do or do not ex-
press Bcl-XL demonstrate that Bcl-XL promotes the sur-
vival of CD282/2 T cells but does not correct the defects in
proliferation and effector differentiation. The ability of Bcl-
XL to promote the survival of CD282/2 T cells is consis-
tent with the hypothesis that reduced expression of this
antiapoptotic protein is most likely responsible for the de-
fective survival of these cells (5–7). Some studies have sug-
gested that CD28 may be important for sustained T cell
proliferation primarily through the ability of CD28-medi-
ated signals to induce antiapoptotic proteins (6), rather than
by promoting the cycling of T cells. Our data indicate that
CD28 plays an additional role in T cell proliferation unre-
lated to its ability to promote survival, because restoring
survival by expressing Bcl-XL is not sufficient to restore T
cell proliferation.
CD282/2 T cells also show markedly deficient Th2 dif-
ferentiation, and Bcl-XL does not correct this defect. One
explanation for this result may be that Th2 differentiation
requires cell cycling (19), CD282/2 T cells do not cycle
normally, and Bcl-XL expression does not correct this de-
fect. Alternatively, CD28 may stimulate Th2 differentiation
by promoting the activation of transcription factors that en-
hance Th2 gene expression, or by making the promoters of
Th2-specific genes accessible to transcription factors (20–
Figure 6. Proliferation of naive T cells from mice re-
constituted with stem cells infected with Bcl-XL virus. Na-
ive CD41 T cells isolated from the lethally irradiated mice
reconstituted with bone marrow stem cells infected with
control or Bcl-XL virus (see Fig. 5) were cultured with mi-
tomycin C–treated APCs and a range of OVA peptide in
96-well plates. Plates were pulsed with [3H]thymidine for
6 h on days 1 and 2 of activation, and the incorporated ra-
dioactivity was measured.
Figure 7. Expression of Bcl-XL in naive T cells does not restore normal
cytokine production in DO.11 CD282/2 T cells. Naive spleen and lymph
node CD41 lymphocytes from the retrovirus-infected stem cell–reconsti-
tuted mice described in the legend to Fig. 5 were activated for 4 d in vitro
with 1 mg/ml of OVA peptide and APCs and analyzed for IL-4 produc-
tion by intracellular cytokine staining. FSC, forward scatter.2037 Dahl et al.
22). It is likely that Bcl-XL does not directly enhance tran-
scription factor activity or chromatin accessibility, and
therefore does not correct the Th2 differentiation defect.
In summary, this study demonstrates that CD28-induced
Bcl-XL–mediated survival function can be separated from
the roles of CD28 in T cell proliferation and differentia-
tion. Therefore, other CD28-induced signals must be nec-
essary to stimulate normal cell expansion and differentia-
tion. The experimental system described in this paper is
currently being used to express a variety of constitutively
active signaling molecules in T cells lacking CD28. Such
a gene complementation approach provides a powerful
method for identifying various downstream mediators im-
portant in the function of cellular receptors such as CD28.
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